DYADIC INTERNATIONAL INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
DYADIC INTERNATIONAL INC (DYAI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.94 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.94, a 45.98% decline year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.74, a 9.43% increase year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.59, a 15.22% increase year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.38, a 71.31% decline year-over-year.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.71, a 6.21% increase from fiscal 2024.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.61, a 11.03% increase from fiscal 2023.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.45, a 67.27% decline from fiscal 2022.
- DYADIC INTERNATIONAL INC share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.43, a 13.31% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.94 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $0.94 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $1.71 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $1.71 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.71 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $1.74 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $1.61 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $1.31 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $1.60 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $1.59 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $1.45 10-K · filed 2025-03-26 | |||
| 2023-09-30 | $1.45 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $1.43 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $1.38 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $4.43 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $4.43 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $4.43 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $4.81 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $5.11 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $5.24 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $5.25 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $5.25 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $5.24 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $5.24 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $5.24 10-Q · filed 2020-08-13 | |||
| 2020-03-31 | $5.24 10-Q · filed 2020-05-14 | |||
| 2019-12-31 | $2.26 10-K · filed 2021-03-30 | |||
| 2019-09-30 | $2.26 10-Q · filed 2019-11-13 | |||
| 2019-06-30 | $2.26 10-Q · filed 2019-08-13 | |||
| 2019-03-31 | $1.89 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $1.44 10-K · filed 2020-03-30 | |||
| 2016-12-31 | $1.61 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |